Halozyme Therapeutics Set to Engage Investors at Key Upcoming Conferences
Halozyme Therapeutics Set to Engage Investors at Key Upcoming Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is poised to deepen its investor relations through participation in several significant conferences. President and CEO Dr. Helen Torley, along with Tram Bui, Vice President of Investor Relations and Corporate Communications, will lead the charge as they interact with potential and current investors. These conferences aim to highlight Halozyme's innovative technologies and their impact on patient care in biopharmaceuticals.
Upcoming Conference Details
1. 2025 Wells Fargo Healthcare Conference
- - Format: Fireside Chat and 1x1 Meetings
- - Presentation Date: Thursday, September 4, 2025
- - Presentation Time: 10:30 AM PT / 1:30 PM ET
- - Location: Boston, MA
2. Morgan Stanley 23rd Annual Global Healthcare Conference
- - Format: Fireside Chat and 1x1 Meetings
- - Presentation Date: Monday, September 8, 2025
- - Presentation Time: 4:45 AM PT / 7:45 AM ET
- - Location: New York, NY
3. H.C. Wainwright 27th Annual Global Investment Conference
- - Format: 1x1 Meetings
- - Presentation Date: Tuesday, September 9, 2025
- - Location: New York, NY
If you are unable to attend in person, Halozyme will provide a live audio webcast of the presentations, accessible via the Investor Relations section on their website. Moreover, recordings of the webcasts will remain available for 90 days post-conference.
About Halozyme
Halozyme Therapeutics is at the forefront of biopharmaceutical innovations. The company’s primary focus is to enhance patient experiences and health outcomes with their disrupter technologies, such as the ENHANZE® drug delivery platform that utilizes the proprietary enzyme rHuPH20. This groundbreaking technology enables the subcutaneous delivery of drugs, aiming to streamline treatment processes and improve patient comfort.
Since its inception, Halozyme has positively impacted over a million lives through the commercial use of ten notable products across more than 100 global markets. Their collaborations with top pharmaceutical firms include giants like Roche, Pfizer, and AbbVie, showcasing the widespread trust in their technology.
In addition to ENHANZE®, Halozyme is also progressing in the development and commercialization of drug-device combinations, leveraging advanced auto-injector technologies. These innovations are designed to offer improved patient adherence, convenience, and overall treatment experience. The company boasts two proprietary products, Hylenex® and XYOSTED®, alongside several collaborations with significant players in the pharmaceutical industry.
Halozyme's headquarters is located in San Diego, CA, with additional offices in Ewing, NJ and Minnetonka, MN, the latter being home to its operational facilities.
As Halozyme continues to engage with investors through these upcoming conferences, the focus remains on revealing their strategic vision and ongoing commitment to transforming patient care within the biopharmaceutical landscape. For the latest updates and information, visit their official website at www.halozyme.com and connect on platforms like LinkedIn and Twitter.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.